Daily Cardiology Research Analysis
Analyzed 153 papers and selected 3 impactful papers.
Summary
Analyzed 153 papers and selected 3 impactful articles.
Selected Articles
1. A Dual-Modal Wearable PPG Smartwatch with AI-Enhanced Correction for High-Accuracy and Continuous AF Burden Assessment.
In a prospective cohort of 1,054 AF patients, an AI framework fusing continuous PPG with intermittent watch-ECG achieved 98.6% sensitivity and 99.3% specificity versus patch ECG, reducing AF burden error by 23.4%. The approach improves long-term burden estimation beyond PPG-only devices without continuous multi-lead ECG.
Impact: Provides a scalable, clinically practical path to precise AF burden tracking in daily life, potentially improving rhythm-control decisions and stroke prevention strategies.
Clinical Implications: Supports more accurate assessment of AF burden for anticoagulation decisions, rhythm-control timing, and post-ablation follow-up, using consumer-grade wearables augmented by AI.
Key Findings
- Dual-modal AI framework (PPG + intermittent watch-ECG) reached 98.60% sensitivity and 99.27% specificity vs patch ECG.
- Mean absolute percentage error for AF burden fell by 23.4% (1.11% to 0.85%).
- Pearson correlation with reference remained extremely high (0.9988), indicating robust burden tracking.
- Prospective validation cohort included 1,054 AF patients undergoing catheter ablation (mean age 62.1 years).
Methodological Strengths
- Prospective validation against a patch-ECG reference standard in a large cohort (n=1,054).
- Hybrid CNN–LSTM model leveraging ECG segments as dynamic anchors to correct PPG classifications.
Limitations
- Burden improvement shown versus patch ECG but without hard clinical outcomes.
- Details on monitoring duration and performance across diverse consumer hardware are not fully delineated.
Future Directions: Pragmatic trials to test whether AI-corrected AF burden monitoring improves anticoagulation, rhythm-control outcomes, and healthcare utilization; validation across devices and populations.
Atrial fibrillation (AF) increases the risk of stroke and heart failure, yet accurate quantification of AF burden in daily life remains difficult. Although smartwatch photoplethysmography (PPG) supports continuous monitoring, complex rhythms and signal noise can impair burden estimation. We developed an AI-enhanced dual-modal framework that combines continuous watch-based PPG (W-PPG) with intermittent single-lead watch-based ECG (W-ECG). A hybrid convolutional neural network-long short-term memory model uses high-fidelity W-ECG segments as dynamic anchors to correct long-term W-PPG classifications. In this prospective validation study, 1,054 patients with AF undergoing catheter ablation (mean age, 62.1 years) were evaluated against patch-based ECG as the reference standard. After ECG-based correction, the system achieved 98.60% sensitivity and 99.27% specificity. The mean absolute percentage error of AF burden decreased by 23.4%, from 1.11% to 0.85%, while the Pearson correlation remained 0.9988. This dual-modal approach offers a scalable and clinically practical solution for long-term AF monitoring, improving burden estimation beyond PPG-only devices without requiring continuous multi-lead ECG. It may support personalized AF management and large-scale cardiovascular screening in real-world settings. (NCT06552468).
2. Effect of Sublingual Nitroglycerin on Absolute Coronary Blood Flow: A Randomized Double-Blind Placebo-Controlled Mechanistic Study.
In a double-blind mechanistic RCT of 40 patients, sublingual nitroglycerin lowered LV preload/afterload and reduced myocardial work, yet increased microvascular resistance and decreased absolute coronary blood flow, despite vessel dilation. These data reconcile the clinical anti-anginal effect with an adaptive reduction in coronary flow.
Impact: This is one of the first human trials quantifying absolute coronary flow responses to nitroglycerin, using intracoronary thermodilution, and reveals an adaptive reduction in flow via increased microvascular resistance.
Clinical Implications: Clinicians should anticipate reduced absolute coronary flow after sublingual NTG and interpret invasive physiologic indices accordingly; symptom relief stems from reduced myocardial work rather than increased flow.
Key Findings
- LV end-diastolic pressure decreased by 38.1% (mean −5.4 mm Hg; P<0.001) after NTG vs placebo.
- Aortic pressure and distal coronary pressure fell by 8.5% and 7.4%, respectively; myocardial work decreased by 21.1% (all P<0.001).
- Despite increased vessel volume, microvascular resistance rose by 8.0% and absolute coronary blood flow declined by 13.3% (P=0.026 and P=0.001, respectively).
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with prespecified hemodynamic endpoints.
- Direct quantification of absolute coronary flow and microvascular resistance via continuous intracoronary thermodilution at 5 and 10 minutes.
Limitations
- Modest sample size limits subgroup analyses and generalizability.
- Short-term physiologic measurements; not powered for clinical outcomes.
Future Directions: Larger multicenter trials should assess symptom trajectories and outcomes across CAD phenotypes and test how NTG timing/dose affects invasive physiologic indices.
BACKGROUND: Nitrates remain a key drug class in the management of angina pectoris. However, their effect on coronary blood flow has never been convincingly demonstrated in humans. OBJECTIVES: The aim of this study was to assess the impact of sublingual nitroglycerin (NTG) on absolute coronary blood flow, coronary resistance, and left ventricular work. METHODS: A randomized, double-blind, placebo-controlled, mechanistic study was conducted. Forty patients with suspected angina underwent cardiac catheterization and randomization to sublingual NTG (n = 20) or a placebo control (n = 20). Using continuous intracoronary thermodilution, baseline absolute coronary blood flow (the primary outcome) and a range of other hemodynamic parameters were measured. Following delivery of the sublingual intervention, repeat measurements were made after 5 and 10 minutes. Between-group differences were analyzed using analysis of covariance. RESULTS: Sublingual NTG resulted in a significant decrease in mean left ventricular end-diastolic pressure of 38.1% (95% CI: 21.8%-54.4%) (estimated mean difference -5.4 mm Hg; 95% CI: -7.8 to -3.1 mm Hg; P < 0.001), along with significant decreases in aortic pressure of 8.5% (95% CI: 5.3%-11.7%) (estimated mean difference -8.6 mm Hg; 95% CI: -12.2% to -5.1%; P < 0.001) and distal coronary pressure of 7.4% (95% CI: 3.7%-11.1%) (estimated mean difference -7.1 mm Hg; 95% CI: -10.6 to -3.7 mm Hg; P < 0.001) after 10 minutes. Myocardial work also decreased by 21.1% (95% CI: 15.4%-26.9%) (estimated mean difference -8.9 mm Hg · s; 95% CI: -11.6 to -6.2 mm Hg · s; P < 0.001). Despite inducing a significant increase in vessel volume, NTG resulted in a significant increase in microvascular resistance of 8.0% (95% CI: 1.1%-14.9%) (estimated mean difference 121.5 Wood units; 95% CI: 15.3-227.8 Wood units; P = 0.026) and a corresponding decrease in absolute coronary blood flow of 13.3% (95% CI: 6.4%-20.2%) (estimated mean difference -8.7 mL/min; 95% CI: -13.4 to -3.9 mL/min; P = 0.001). CONCLUSIONS: Sublingual NTG induced a significant decrease in left ventricular preload and afterload, resulting in a marked decrease in myocardial work. This was associated with a significant and adaptive decrease in absolute coronary blood flow.
3. HERZCHECK: Early Detection of Subclinical Preheart Failure Using Mobile Cardiac Magnetic Resonance and Telemedicine in Rural and Underressourced Regions.
In 4,509 at-risk, asymptomatic adults screened via mobile, telemedicine-supervised CMR, subclinical pre-HF (GLS ≥ −15%) was present in 22.7% and was detected a mean 6.7 years earlier than symptom-based diagnosis in matched claims data. This demonstrates scalable early detection in underserved regions.
Impact: Provides a standardized, mobile imaging pathway to identify pre-HF years before symptoms, enabling targeted prevention where access is limited.
Clinical Implications: Supports CMR-GLS screening workflows for high-risk asymptomatic adults, informing early lifestyle, pharmacologic prevention, and surveillance strategies.
Key Findings
- Mobile, telemedicine-supervised CMR identified subclinical pre-HF (GLS ≥ −15%) in 22.7% of 4,509 at-risk individuals.
- Pre-HF was detected on average 6.7 years earlier than symptom-based HF diagnosis in matched claims controls.
- Feasible, contrast-free short CMR protocol deployed across 12 rural/underresourced sites.
Methodological Strengths
- Large multicenter cohort with standardized imaging and claims-based comparator for lead-time estimation.
- Clear, pre-specified GLS cutoff and entropy-balanced matching approach.
Limitations
- Cross-sectional design without randomized outcome follow-up to confirm preventive benefit.
- Generalizability beyond German rural settings and operational costs require further evaluation.
Future Directions: Prospective trials to test whether pre-HF identification plus targeted interventions reduce incident HF and healthcare utilization; health-economic analyses in diverse health systems.
BACKGROUND: There is a growing consensus that screening for subclinical preheart failure (HF) may reduce the burden of symptomatic HF by allowing for timely preventive interventions. However, validated screening algorithms are currently lacking. The aim of this study was to evaluate a fully mobile telemedically supervised cardiac magnetic resonance, as a simple standardized, and ubiquitously applicable screening algorithm for subclinical pre-HF in rural and underresourced regions. METHODS: HERZCHECK was a cross-sectional cohort study conducted at 12 sites across rural and underresourced regions of Germany. Asymptomatic participants (40-69 years) with ≥1 cardiovascular risk factor-obesity, smoking, arterial hypertension, diabetes, hypercholesterolemia, or chronic kidney disease-were enrolled and underwent telemedically supervised contrast-free short cardiac magnetic resonance in mobile screening units. Subclinical pre-HF was diagnosed using a predefined cutoff of global longitudinal strain ≥-15%. A matched and entropy-balanced control cohort constructed from claims data was used to determine the time difference between detection of subclinical pre-HF in HERZCHECK and the first symptom-based diagnosis of HF within the standard of care. RESULTS: Between June 2021 and April 2023, 4666 participants were enrolled in the study, of which 4509 participants were included in the final analysis. The prevalence of subclinical pre-HF in the studied at-risk population was 22.7% (95% CI, 21.5%-23.9%). Global longitudinal strain-based screening identified subclinical pre-HF 6.7 years before the average onset of symptomatic HF within the standard of care (n=8420). CONCLUSIONS: Subclinical pre-HF affects approximately one-fourth of the at-risk population in rural and underresourced regions. The HERZCHECK approach identifies patients suitable for targeted preventive interventions ≈7 years earlier than the standard of care. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05122793.